These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 30530925)

  • 1. Efavirenz pharmacokinetics during pregnancy and infant washout.
    Kreitchmann R; Schalkwijk S; Best B; Wang J; Colbers A; Stek A; Shapiro D; Cressey T; Mirochnick M; Burger D
    Antivir Ther; 2019; 24(2):95-103. PubMed ID: 30530925
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efavirenz pharmacokinetics during the third trimester of pregnancy and postpartum.
    Cressey TR; Stek A; Capparelli E; Bowonwatanuwong C; Prommas S; Sirivatanapa P; Yuthavisuthi P; Neungton C; Huo Y; Smith E; Best BM; Mirochnick M;
    J Acquir Immune Defic Syndr; 2012 Mar; 59(3):245-52. PubMed ID: 22083071
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Safety and pharmacokinetics of dolutegravir in pregnant mothers with HIV infection and their neonates: A randomised trial (DolPHIN-1 study).
    Waitt C; Orrell C; Walimbwa S; Singh Y; Kintu K; Simmons B; Kaboggoza J; Sihlangu M; Coombs JA; Malaba T; Byamugisha J; Amara A; Gini J; Else L; Heiburg C; Hodel EM; Reynolds H; Mehta U; Byakika-Kibwika P; Hill A; Myer L; Lamorde M; Khoo S
    PLoS Med; 2019 Sep; 16(9):e1002895. PubMed ID: 31539371
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dolutegravir pharmacokinetics in pregnant and postpartum women living with HIV.
    Mulligan N; Best BM; Wang J; Capparelli EV; Stek A; Barr E; Buschur SL; Acosta EP; Smith E; Chakhtoura N; Burchett S; Mirochnick M;
    AIDS; 2018 Mar; 32(6):729-737. PubMed ID: 29369162
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacokinetics of an increased atazanavir dose with and without tenofovir during the third trimester of pregnancy.
    Kreitchmann R; Best BM; Wang J; Stek A; Caparelli E; Watts DH; Smith E; Shapiro DE; Rossi S; Burchett SK; Hawkins E; Byroads M; Cressey TR; Mirochnick M
    J Acquir Immune Defic Syndr; 2013 May; 63(1):59-66. PubMed ID: 23392467
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacokinetics of tenofovir during pregnancy and postpartum.
    Best BM; Burchett S; Li H; Stek A; Hu C; Wang J; Hawkins E; Byroads M; Watts DH; Smith E; Fletcher CV; Capparelli EV; Mirochnick M;
    HIV Med; 2015 Sep; 16(8):502-11. PubMed ID: 25959631
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacokinetics of efavirenz and treatment of HIV-1 among pregnant women with and without tuberculosis coinfection.
    Dooley KE; Denti P; Martinson N; Cohn S; Mashabela F; Hoffmann J; Haas DW; Hull J; Msandiwa R; Castel S; Wiesner L; Chaisson RE; McIlleron H;
    J Infect Dis; 2015 Jan; 211(2):197-205. PubMed ID: 25081933
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Atazanavir pharmacokinetics with and without tenofovir during pregnancy.
    Mirochnick M; Best BM; Stek AM; Capparelli EV; Hu C; Burchett SK; Rossi SS; Hawkins E; Basar M; Smith E; Read JS;
    J Acquir Immune Defic Syndr; 2011 Apr; 56(5):412-9. PubMed ID: 21283017
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacokinetic and Pharmacodynamic Comparison of Once-Daily Efavirenz (400 mg vs. 600 mg) in Treatment-Naïve HIV-Infected Patients: Results of the ENCORE1 Study.
    Dickinson L; Amin J; Else L; Boffito M; Egan D; Owen A; Khoo S; Back D; Orrell C; Clarke A; Losso M; Phanuphak P; Carey D; Cooper DA; Emery S; Puls R;
    Clin Pharmacol Ther; 2015 Oct; 98(4):406-16. PubMed ID: 26044067
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacokinetics, Pharmacodynamics, and Pharmacogenetics of Efavirenz 400 mg Once Daily During Pregnancy and Post-Partum.
    Lamorde M; Wang X; Neary M; Bisdomini E; Nakalema S; Byakika-Kibwika P; Mukonzo JK; Khan W; Owen A; McClure M; Boffito M
    Clin Infect Dis; 2018 Aug; 67(5):785-790. PubMed ID: 30124823
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Raltegravir versus efavirenz in antiretroviral-naive pregnant women living with HIV (NICHD P1081): an open-label, randomised, controlled, phase 4 trial.
    João EC; Morrison RL; Shapiro DE; Chakhtoura N; Gouvèa MIS; de Lourdes B Teixeira M; Fuller TL; Mmbaga BT; Ngocho JS; Njau BN; Violari A; Mathiba R; Essack Z; Pilotto JHS; Moreira LF; Rolon MJ; Cahn P; Prommas S; Cressey TR; Chokephaibulkit K; Werarak P; Laimon L; Hennessy R; Frenkel LM; Anthony P; Best BM; Siberry GK; Mirochnick M
    Lancet HIV; 2020 May; 7(5):e322-e331. PubMed ID: 32386720
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Population Pharmacokinetics Analysis To Inform Efavirenz Dosing Recommendations in Pediatric HIV Patients Aged 3 Months to 3 Years.
    Luo M; Chapel S; Sevinsky H; Savant I; Cirincione B; Bertz R; Roy A
    Antimicrob Agents Chemother; 2016 Jun; 60(6):3676-86. PubMed ID: 27067333
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Raltegravir pharmacokinetics during pregnancy.
    Watts DH; Stek A; Best BM; Wang J; Capparelli EV; Cressey TR; Aweeka F; Lizak P; Kreitchmann R; Burchett SK; Shapiro DE; Hawkins E; Smith E; Mirochnick M;
    J Acquir Immune Defic Syndr; 2014 Dec; 67(4):375-81. PubMed ID: 25162818
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Hair concentrations of antiretrovirals predict viral suppression in HIV-infected pregnant and breastfeeding Ugandan women.
    Koss CA; Natureeba P; Mwesigwa J; Cohan D; Nzarubara B; Bacchetti P; Horng H; Clark TD; Plenty A; Ruel TD; Achan J; Charlebois ED; Kamya MR; Havlir DV; Gandhi M
    AIDS; 2015 Apr; 29(7):825-30. PubMed ID: 25985404
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Reduced indinavir exposure during pregnancy.
    Cressey TR; Best BM; Achalapong J; Stek A; Wang J; Chotivanich N; Yuthavisuthi P; Suriyachai P; Prommas S; Shapiro DE; Watts DH; Smith E; Capparelli E; Kreitchmann R; Mirochnick M;
    Br J Clin Pharmacol; 2013 Sep; 76(3):475-83. PubMed ID: 23305215
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacokinetics of rifampin and isoniazid in tuberculosis-HIV-coinfected patients receiving nevirapine- or efavirenz-based antiretroviral treatment.
    Bhatt NB; Barau C; Amin A; Baudin E; Meggi B; Silva C; Furlan V; Grinsztejn B; Barrail-Tran A; Bonnet M; Taburet AM;
    Antimicrob Agents Chemother; 2014 Jun; 58(6):3182-90. PubMed ID: 24663014
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacokinetics of Rilpivirine in HIV-Infected Pregnant Women.
    Tran AH; Best BM; Stek A; Wang J; Capparelli EV; Burchett SK; Kreitchmann R; Rungruengthanakit K; George K; Cressey TR; Chakhtoura N; Smith E; Shapiro DE; Mirochnick M;
    J Acquir Immune Defic Syndr; 2016 Jul; 72(3):289-96. PubMed ID: 26918544
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacokinetics of Efavirenz 600 mg Once Daily During Pregnancy and Post Partum in Ghanaian Women Living With HIV.
    Lartey M; Kenu E; Lassey A; Ntumy M; Ganu V; Sam M; Boamah I; Gilani FS; Yang H; Burch GM; Norman J; Peloquin CA; Kwara A
    Clin Ther; 2020 Sep; 42(9):1818-1825. PubMed ID: 32811669
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of pregnancy on emtricitabine pharmacokinetics.
    Stek AM; Best BM; Luo W; Capparelli E; Burchett S; Hu C; Li H; Read JS; Jennings A; Barr E; Smith E; Rossi SS; Mirochnick M
    HIV Med; 2012 Apr; 13(4):226-35. PubMed ID: 22129166
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Hair and plasma data show that lopinavir, ritonavir, and efavirenz all transfer from mother to infant in utero, but only efavirenz transfers via breastfeeding.
    Gandhi M; Mwesigwa J; Aweeka F; Plenty A; Charlebois E; Ruel TD; Huang Y; Clark T; Ades V; Natureeba P; Luwedde FA; Achan J; Kamya MR; Havlir DV; Cohan D;
    J Acquir Immune Defic Syndr; 2013 Aug; 63(5):578-84. PubMed ID: 24135775
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.